Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool December 23, 2003 Jeff Hwang	Bad, Bad Baxter The medical products company issues its latest in a series of earnings warnings.
The Motley Fool January 28, 2005 Brian Gorman	Baxter Plods On 2005 looks like another year of transition for Baxter International. The medical products and services concern reported that after currency adjustments, fourth-quarter 2004 revenue of $2.6 billion was essentially flat compared with the same period in 2003.
The Motley Fool July 20, 2007 Brian Orelli	Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports.
The Motley Fool April 20, 2006 Stephen D. Simpson	Baxter Bags Better Margins This is a great business -- but only at the right price. Investors, this story has to be bought cheap. At today's prices, is it cheap enough?
Chemistry World March 28, 2014 Phillip Broadwith	Baxter aims to divide and conquer US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.
The Motley Fool November 3, 2011 Dan Caplinger	Has Baxter International Become the Perfect Stock? Baxter needs to keep working on getting its debt levels down and seek out new growth opportunities. With favorable demographic winds at its back, Baxter could be the rare stock to actually reach perfection.
The Motley Fool April 17, 2009 Robert Steyer	The Steady BAX Beat Baxter International's diverse medical offerings continue to produce prosperity.
The Motley Fool April 18, 2008 Brian Orelli	Recalls Can't Beat Baxter In spite of charges for two recalls, Baxter posts a decent quarter.
The Motley Fool October 19, 2007 Brian Orelli	Baxter Gets Pumped Up Medical-device maker Baxter puts in a nice quarter despite two recent FDA recalls.
Pharmaceutical Executive April 1, 2006 Ron Feemster	Thought Leader: Q&A with Joel A. Tune Pharma still enlists contract manufacturers as safety valves, but today's drug developers have also begun to outsource the production of increasingly complicated compounds while they are still in clinical trials.
The Motley Fool March 10, 2008 Brian Orelli	Breakup Weighs Down APP It's going to take awhile for APP Pharmaceuticals to reward investors.
The Motley Fool February 21, 2008 Brian Lawler	A Bit of Irony From the FDA The agency has a mixed message on drug importation, as evidenced in the recent possible contamination of China-produced Heparin.
The Motley Fool October 20, 2005 Stephen D. Simpson	Baxter Needs Growth Infusion This is a fine health-care company, but a sluggish top line suggests there are limits to how far it can go. Trading at nearly 20 times forward earnings, it seems like expectations of a growth revival are already in the stock.
IndustryWeek January 1, 2009 David Drickhamer	Baxter Mexico: IW Best Plants Profile 2008 Lean Medical Marvel: Baxter Mexico transforms its production processes from the bottom up.
The Motley Fool September 24, 2008 Brian Orelli	Hey, You! Stop! The FDA has ordered Baxter and Hospira to stop making their ophthalmic balanced salt solutions within 60 days.
Pharmaceutical Executive September 1, 2008	How Do You Solve a Problem Like Manufacturing? Outsourcing saves pharmaceutical companies money -- except when it doesn't. Here's how to decide what to do.
The Motley Fool March 7, 2008 Brian Lawler	A Little Too Much Drug Variability Another drugmaker has to recall batches of its compound.
The Motley Fool February 29, 2008 Brian Orelli	Bigger Recall, No Big Deal Baxter increases its recall of heparin, but investors shouldn't be that worried.
The Motley Fool January 31, 2006 Stephen D. Simpson	Guidance Puts ICU Medical in the Trauma Ward This oft-volatile stock had a strong fourth quarter, but weak guidance. Even with today's steep drop in price, the shares aren't cheap enough to be interesting.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
The Motley Fool October 16, 2009 Robert Steyer	Baxter Beats Again -- the Streak Is Alive! The drug, device, and medical services giant beats Wall Street earnings estimates by a penny, but flat sales signal caution.
The Motley Fool November 10, 2005 Stephen D. Simpson	Hospitable Treatment for Hospira Solid margins fuel strong earnings at the hybrid generics - medical distributor. Buying this stock wisely may be the key to good long-term returns.
Fast Company April 2004 Keith H. Hammonds	Moment of Truth? It has been a tortuous year for Harry M. Jansen Kraemer Jr., CEO of Baxter International Inc. Back in November 2002, we lauded Kraemer's forthright leadership as his company confronted the deaths of 53 patients due to contaminated dialysis filters made by a Baxter subsidiary. Now Kraemer is out of a job.
Chemistry World December 6, 2012 Andrew Turley	Baxter to pay $4bn for dialysis firm US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion
The Motley Fool April 10, 2008 Brian Orelli	The News for Baxter Just Got Worse These heparin-related deaths aren't associated with Baxter's product, but they still might spell trouble for the company.
Fast Company November 2002 Keith H. Hammonds	Harry Kraemer's Moment of Truth In an era when the business section read like the police blotter, the CEO of medical products and pharmaceutical company Baxter International faced a tough ethical dilemma. And he did something noteworthy: He actually did the right thing.
The Motley Fool September 27, 2007 Billy Fisher	Baxter Looking to Bounce Back Shares of the medical device maker finally rebound following a company recall of infusion pumps.
The Motley Fool January 23, 2009 Robert Steyer	BAX to the Future After minding its own business, Baxter International starts thinking about acquisitions again.
IndustryWeek June 1, 2003 John S. McClenahen	Waking Up To A New World Is U.S. manufacturing in the midst of a nightmare or a dream come true?
The Motley Fool August 30, 2007 Brian Orelli	Forget What Your Drug Was Approved For Baxter stages a new trial for an old drug.
The Motley Fool August 26, 2008 Brian Orelli	Baxter Ready to Sop Up Additional Revenue The health-care giant licenses a surgical sponge in clinical development.